Impact and Mechanisms of Sotagliflozin on Liver-Associated Disorders in Cystic Fibrosis Models
Publisher：Unknown
·Published at: 2025-12-13
A discussion regarding how the SGLT1/2 inhibitor sotagliflozin influences liver-associated disorders within cystic fibrosis models, specifically seeking to understand the potential underlying mechanisms of this interaction.
Loading...